| Tocilizumab reduces mortality and mechanical ventilation requirement in hospitalized patients with COVID-19 and hypoxemia. |
| Mortality benefit is confirmed and amplified in the severe COVID-19 group but not in the non-severe COVID-19 group. |
| Mechanical ventilation incidence benefit is confirmed in both groups (severe COVID-19 group and non-severe COVID-19 group). |
| Tocilizumab is effective in COVID-19 pneumonia. The greatest benefit is observed in severe COVID-19 pneumonia. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.